(Q36543803)

14 August 2017

1 reference

title

Clinical results of vaccine therapy for cancer: learning from history for improving the future (English)

1 reference

14 August 2017

Aniruddha Choudhury

1

1 reference

14 August 2017

Szilvia Mosolits

2

1 reference

14 August 2017

Parviz Kokhaei

3

1 reference

14 August 2017

Lotta Hansson

4

1 reference

14 August 2017

Marzia Palma

5

1 reference

14 August 2017

Håkan Mellstedt

6

1 reference

14 August 2017

publication date

1 January 2006

1 reference

Advances in Cancer Research

14 August 2017

published in

1 reference

14 August 2017

volume

95

1 reference

14 August 2017

page(s)

147-202

1 reference

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Interferon-alpha in tumor immunity and immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Regulatory T-cell therapy: is it ready for the clinic?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Granulocyte-macrophage colony-stimulating factor-cultured bone marrow-derived macrophages reveal accessory cell function and synthesis of MHC class II determinants in the absence of external stimuli

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

A phase II study of G17DT in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

1 reference

7 January 2021

Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Vaccination as a treatment for breast or ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Role of LAG-3 in regulatory T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

In vitro preparation and functional assessment of human monocyte-derived dendritic cells-potential antigen-specific modulators of in vivo immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Phase II Randomized Trial of Autologous Formalin-Fixed Tumor Vaccine for Postsurgical Recurrence of Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Immunotherapy for pancreatic cancer - science driving clinical progress

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Carcinoembryonic antigen-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Combinations of anticancer drugs and immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Cancer vaccines: pessimism in check

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Immunotherapy with Autologous, Human Dendritic Cells Transfected with Carcinoembryonic Antigen mRNA

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Tumour-associated antigens in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

A phase I/II trial of oxidized autologous tumor vaccines during the "watch and wait" phase of chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

DNA fusion gene vaccines against cancer: from the laboratory to the clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Dendritic cell-based vaccination in solid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Cancer vaccines: pessimism in check

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Interleukin-12: a cytokine at the interface of inflammation and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma--a phase 1 study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Antigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Optimizing dendritic cell-based immunotherapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2995005-2

7 January 2021

10.1016/S0065-230X(06)95005-2

Identifiers

DOI

1 reference

14 August 2017

1 reference